

BEKEMV[®] ▼(eculizumab)

Physician's Guide

Important information for healthcare providers about serious adverse events or reactions with BEKEMV (eculizumab)

- ▼ You can help by reporting any side effects via the instructions given in section "Reporting Adverse Drug Reactions"



BEKEMV[®]_Physicians Guide_Version 1.0, December 2024

CONTENTS

PAGE

IMPORTANT INFORMATION	3
ECULIZUMAB	4
ECULIZUMAB INDICATIONS	4
IMPORTANT SAFETY INFORMATION	5
SIGNS AND SYMPTOMS OF SEVERE INFECTIONS	6
OTHER SERIOUS ADVERSE REACTIONS	8
SORBITOL CONTENT WARNING	8
RISKS ASSOCIATED WITH DISCONTINUATION OF ECULIZUMAB	9
REPORTING ADVERSE DRUG REACTIONS	10

The aim of this brochure is to educate and/or remind healthcare professionals about the selected prevention measures, detection, careful monitoring and/or proper management of selected safety concerns associated with eculizumab.



IMPORTANT INFORMATION

Vaccination/Prophylaxis antibiotic Certificate

In order to minimize the risk of inappropriate use of eculizumab, distribution of the medicinal product is only possible after your written confirmation at the 1st order that you as the hospital understand that the patient received or will receive meningococcal vaccination and/or antibiotic prophylaxis.

Eculizumab

The active drug substance in BEKEMV, is a recombinant humanised monoclonal antibody targeting the complement protein C5.

Eculizumab is a terminal complement inhibitor that prevents the generation of the terminal complement complex C5b-9. The early components of complement activation essential for opsonisation of microorganisms, initiation of immune response (both humoral and cellular) and clearance of immune complexes are preserved.

ECULIZUMAB INDICATION

Eculizumab is indicated in:

- Adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

IMPORTANT SAFETY INFORMATION

Eculizumab is contraindicated in patients with hereditary fructose intolerance (HFI) regardless of their age, and in babies and children under 2 years of age who may not yet be diagnosed with HFI. Please see sorbitol content warning on page 8.

Risk of severe infection and sepsis

Due to its mechanism of action, the use of eculizumab increases the risk of severe infection and sepsis, especially meningococcal infection (*Neisseria meningitidis*) for the patient. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients.

The following steps must be taken to minimise the risk of infection and the risk of poor outcomes following infection:

Neisseria meningitidis: Vaccination and antibiotic prophylaxis

- Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection.
- Vaccines against serogroups A, C, Y, W 135 and B (where available) are recommended.
- Vaccinate according to current national vaccination guidelines for vaccine use.²
- Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary.
- In young children for whom there is no vaccine recommended or available for use, in patients for whom the vaccine is contraindicated and in patients treated with eculizumab less than 2 weeks after receiving a meningococcal vaccine, treat with antibiotic prophylaxis throughout the treatment period or until 2 weeks after the vaccination can be given.

Haemophilus influenzae and pneumococcal infections in children: Vaccination

- **Patients receiving eculizumab for PNH:** Vaccinate patients less than 18 years against *Haemophilus influenzae* and pneumococcal infections according to national vaccination guidelines at least 2 weeks prior to initiation of eculizumab therapy and strictly adhere to the national vaccination recommendations for each age group.

Impact of vaccination on underlying disease

Vaccination or revaccination may further activate complement and, as a result, patients with complement-mediated diseases, including PNH, may experience increased signs and symptoms of their underlying disease, such as haemolysis. Therefore, patients should be closely monitored for disease symptoms after recommended vaccination.

SIGNS AND SYMPTOMS OF SEVERE INFECTION

Meningococcal infection

- **Sepsis** is a common presentation of meningococcal infections in patients treated with eculizumab.
- **Monitor** your patients for early signs of meningococcal infections.
- **Evaluate** immediately if infection is suspected, and treat with antibiotics if necessary.
- **Provide the Patient/Parent Information Brochure. Explain the brochure** content to patients or parents/caregivers of patients being treated with **eculizumab** in order to increase their awareness of potential serious infections and the relevant signs and symptoms which include:

- Headache with nausea or vomiting
- Headache with a stiff neck or back
- Fever
- Rash
- Confusion
- Severe muscle ache combined with flu-like symptoms
- Sensitivity to light



In children additional signs and symptoms to those listed above may include:

- Rapid breathing
- Cold hands and feet
- Refusing food and/or vomiting
- Unusual crying or moaning
- Stiff neck
- Being drowsy or difficult to wake
- Irritability
- Shaking and leg pain

- **Provide a Patient Safety Card** to patients being treated with **eculizumab** and explain that they must carry it at all times and for 3 months after last dose and show it to healthcare professionals they see.
- Physicians must discuss the benefits and risks of eculizumab therapy with patients/parents.
- **Inform patients that if they/their child suspect they may have an infection, they should seek urgent medical advice/caregivers.**



Ensure that the parents/legal guardians can confidently identify typical symptoms of headache, fever, and neck stiffness which may be hard to detect in younger children, so train them to be aware of other symptoms including inactivity, irritability, vomiting, and poor feeding and to seek urgent medical attention.

Other systemic infections

Neisseria species infections

Due to its mechanism of action, eculizumab therapy should be administered with caution to patients with active systemic infections (particularly due to *Neisseria* and encapsulated bacteria). Serious infections with *Neisseria* species (other than *Neisseria meningitidis*), including disseminated gonococcal infections, have been reported.

Physicians should advise patients about gonorrhoea prevention, based on advice for prevention of other sexually transmitted infections that includes use of appropriate barrier contraception and condoms in sexually active patients.

Aspergillus infection

Cases of *Aspergillus* infections, some of them fatal, have been reported in eculizumab-treated patients.

Underlying risk factors such as, long term steroid use, immunosuppressive treatments, severe pancytopenia, exposure to construction or demolition sites, and pre-existing lung impairment or *Aspergillus* infection should be considered. If one of the above risk factors is identified before starting treatment with eculizumab, appropriate measures to mitigate the risk of *Aspergillus* infection are advisable.

OTHER SERIOUS ADVERSE REACTIONS

Infusion reactions including anaphylaxis

As with all therapeutic proteins, administration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis).

Patients should be monitored for one hour following infusion. If an adverse event occurs during the administration of eculizumab, the infusion may be slowed or stopped at the discretion of the physician. If the infusion is slowed, the total infusion time may not exceed two hours in adults and adolescents (aged 12 years to under 18 years) and four hours in children aged less than 12 years.

Immunogenicity

Infrequent antibody responses have been detected in eculizumab-treated patients across clinical studies. There has been no observed correlation of antibody development to clinical response or adverse events.

SORBITOL CONTENT WARNING

Each ml of this medicinal product contains 50 mg of sorbitol (E420). Patients with hereditary fructose intolerance (HFI) must not take this medicine. In HFI patients more than 2 years old, a spontaneous aversion for fructose-containing foods develops and may be combined with the onset of symptoms (vomiting, gastrointestinal disorders, apathy, height and weight retardation). Therefore, a detailed history with regard to HFI symptoms has to be taken of each patient prior to receiving eculizumab.

After intravenous administration of a sorbitol-containing medicine like eculizumab, patients with HFI may present with hypoglycemia, metabolic acidosis, seizures, coma and could be life-threatening. In case of inadvertent administration and suspicion of fructose intolerance the infusion has to be stopped immediately, normal glycaemia has to be re-established and organ function has to be stabilized by means of intensive care. Chronic exposure to sorbitol in patients with HFI may cause failure to thrive, kidney and liver failure.

Babies and children (below 2 years of age) may not yet be diagnosed with HFI. Medicines containing sorbitol/fructose given intravenously may be life-threatening and must be contraindicated in this population.

RISKS ASSOCIATED WITH DISCONTINUATION OF eculizumab

Serious intravascular haemolysis

Patients who start eculizumab as treatment for PNH should continue receiving eculizumab, even if they feel better.

However, patients who discontinue treatment with eculizumab should be monitored for signs and symptoms of serious intravascular haemolysis and other reactions for at least 8 weeks. There is serious haemolysis when serum LDH is greater than pre-treatment LDH and patients have any of the following criteria: PNH clone size reductions of >25% in 1 week or less; haemoglobin <5g/dL or haemoglobin falls of >4g/dL in 1 week or less; angina; change in mental status; serum creatinine increase of 50%; thrombosis.

If serious haemolysis occurs, consider the following procedures/treatments: blood transfusion (packed RBCs) or exchange transfusion if PNH RBCs >50% of total RBCs by flow cytometry; anticoagulation; corticosteroids, or reconstitution of eculizumab

please refer to the SPC for further information

REPORTING ADVERSE DRUG REACTIONS

Contact details for adverse event reporting or to request further information. Any suspected adverse reactions should be reported immediately to local Amgen safety contacts or the National Pharmacovigilance Center

Amgen Local Safety Contacts

Tel: +966 112 799328

E-mail: safety-mea@amgen.com

The National Pharmacovigilance Centre (NPC)

Saudi Food and Drug Authority (SFDA)

SFDA call center 19999

E-mail: npc.drug@sfd.gov.sa Online: <http://ade.sfd.gov.sa/>

Should you have any questions or require additional information regarding the use of BEKEMV, you can refer to the Patient Information Leaflet (PIL), or contact Medical Information by e-mail at: medinfo-mea@amgen.com

This document is approved by the Executive Directorate of Pharmacovigilance at SFDA

